- Report
- November 2023
- 250 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
- Report
- March 2023
- 262 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
- Report
- September 2022
- 293 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
- Report
- June 2021
- 245 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Report
- March 2021
- 202 Pages
Global
From €2328EUR$2,558USD£1,977GBP
€3326EUR$3,654USD£2,825GBP
- Book
- February 2014
- 400 Pages
- Book
- February 2013
- 512 Pages
- Book
- October 2009
- 912 Pages
- Book
- August 2022
- 672 Pages
- Book
- August 2022
- 736 Pages
- Book
- August 2010
- 656 Pages
The Immunoglobulin market is a segment of the Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. Immunoglobulin (Ig) is a type of protein found in the blood that helps fight infection and disease. It is used to treat a variety of immune-related conditions, including autoimmune diseases, allergies, and infections. Immunoglobulin therapies are typically administered intravenously or subcutaneously, and can be used to replace or supplement the body's natural Ig production.
The Immunoglobulin market is highly competitive, with a number of companies offering a range of products. These products vary in terms of dosage, delivery method, and cost. Companies in the market are focused on developing new therapies and improving existing ones, as well as expanding their product portfolios.
Some of the major companies in the Immunoglobulin market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more